Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.0179 USD
−3.03 M USD
0.00 USD
78.16 M
About Inhibitor Therapeutics Inc.
Sector
CEO
Frank E. O'Donnell
Headquarters
Tampa
Website
Founded
1992
FIGI
BBG000BW1RH7
Inhibitor Therapeutics, Inc. engages in the discovery, development, and commercialization of therapeutics for patients with cancer. It focuses on SUBA-Itraconazole, a patented, oral formulation of Itraconazole, for treatment of prostate and lung cancers. The company was founded on September 30, 1992 and is headquartered in Tampa, FL.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of INTI is 0.0800 USD — it has decreased by −5.88% in the past 24 hours. Watch Inhibitor Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Inhibitor Therapeutics Inc. stocks are traded under the ticker INTI.
INTI stock has risen by 21.21% compared to the previous week, the last month showed zero change in price, over the last year Inhibitor Therapeutics Inc. has showed a −38.46% decrease.
INTI reached its all-time high on Feb 17, 2000 with the price of 30.0000 USD, and its all-time low was 0.0020 USD and was reached on Dec 30, 2011. View more price dynamics on INTI chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
INTI stock is 6.25% volatile and has beta coefficient of 0.87. Track Inhibitor Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Inhibitor Therapeutics Inc. there?
Today Inhibitor Therapeutics Inc. has the market capitalization of 13.79 M, it has increased by 2.56% over the last week.
Yes, you can track Inhibitor Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Inhibitor Therapeutics Inc. is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
INTI net income for the last quarter is −730.96 K USD, while the quarter before that showed −501.69 K USD of net income which accounts for −45.70% change. Track more Inhibitor Therapeutics Inc. financial stats to get the full picture.
No, INTI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 16, 2024, the company has 9.00 employees. See our rating of the largest employees — is Inhibitor Therapeutics Inc. on this list?
Like other stocks, INTI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Inhibitor Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Inhibitor Therapeutics Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Inhibitor Therapeutics Inc. stock shows the neutral signal. See more of Inhibitor Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.